The goal is to identify people at risk for RA &, perhaps, prevent its onset.
Latest News
Catch Your Breath: Understanding Interstitial Lung Disease in Rheumatoid Arthritis
The session highlighted the importance of correctly identifying and treating patients with RA-ILD early in their disease course.
Can Cultural Humility Conquer Systemic Inequity in Pediatric Rheumatology?
Doctors and patient advocates urged the rheumatology community to address the drastic inadequacies in care faced by marginalized people in a session held at ACR Convergence 2024.
It’s Not Just Joint Pain
Experts offered perspectives on how symptoms of rheumatic disease, such as fatigue, affect the physical, cognitive and emotional health of patients and offered solutions.
ACR Honors Distinguished Fellows: Class of 2024
At ACR Convergence 2024, the ACR honored clinical and research fellows in programs from New York to California and points between.
The 2024 ACR Awards of Distinction
The 2024 ACR Awards of Distinction honor members for their outstanding contributions to the field of rheumatology.
B Cell-Depleting Therapy in SLE
“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
How to Write an Effective Fellowship Application Essay
I read a lot of essays and, believe it or not, I’ve been known to write a few on occasion as well. The majority of…
Anti-Infliximab Antibodies Predict Response in Axial Spondyloarthritis
Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.